STAMPEDE2

STAMPEDE2 is a trial testing new treatments in men with prostate cancer that has spread to other parts of the body (metastatic prostate cancer). It tests these treatments when the cancer is hormone-sensitive, which means that it is at a stage where it is responsive to treatment with hormone therapy.

STAMPEDE2 is a set of randomised controlled trials (called comparisons) testing the addition of new treatments to standard of care (SoC):

• Treatment S: Stereotactic Ablative Body Radiotherapy (SABR): a type of radiotherapy. This comparison is testing whether giving targeted doses of radiotherapy (SABR) to the metastatic sites where the cancer has spread outside of the prostate, can control further spread of the disease and improve survival. 

• Treatment P: ¹⁷⁷Lu-PSMA-617: a nuclear medicine therapy. This comparison is looking at whether using a radioactive material targeted at the surface of prostate cancer cells can control the spread of the disease and prolong survival. Prostate Specific Membrane Antigen-Lutetium (PSMA) is a radioactive material that is designed to target cancer cells and kill the tumour. 

• Treatment N: Nira-AA+P: an oral drug therapy. This comparison is only available to men whose tumour has particular genetic changes. Patients who have not yet commenced Androgen Receptor Signaling Inhibitor (ARSI) therapy will be asked if they consent for their tumour tissue taken at diagnosis to be sent away for testing at a central laboratory. If the test result is positive, then the patient will be eligible to take part in Comparison N. It is predicted that 10-15% of patients will be positive for genetic changes that make them eligible for participation in this comparison. (Please note that this part of the STAMPEDE2 trial will not be activated).

Trying to find out about the original STAMPEDE trial? For information on STAMPEDE and previous comparison results, visit: About STAMPEDE.